Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant plus palonosetron versus granisetron for prevention of chemotherapy-induced nausea and vomiting during hematopoietic progenitor transplantation
2006-000755-18Phase 4Active
- Sponsor
- Fundación PETHEMA
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Aprepitant + palonosetron with Granisetron control (2 arms). Primary endpoints: Complete response rate, Complete protection rate and 6 more. Started Apr 2006; status: active.
02
Drugs
aprepitantpalonosetrongranisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2006-000755-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000755-18.